Latest Eisai News & Updates
See the latest news and media coverage for Eisai. We track all announcements, press releases, and industry mentions in real time, all in one place.
Human health care company
eisai.com- Headquarters
- Bunkyo-Ku, Japan
- Company type
- Public company
- Number of employees
- 1,000–5,000
Last updated
Latest news about Eisai
In short: Eisai achieved major regulatory milestones for its Alzheimer's drug Leqembi and expanded its oncology portfolio through new licensing agreements.
Company announcements
-
Eisai opens new Global Capability Centre
The IT hub in Visakhapatnam, India, standardizes global IT operations and drives digital transformation. An opening ceremony celebrated its launch.
-
Eisai receives human capital awards for third year
Eisai earns 'Thought Leaders of Human Capital 2025' and 'Human Capital Management Excellence 2025 Gold Award' for excellent management and disclosure.
-
Eisai announces FDA acceptance of LEQEMBI IQLIK sBLA
The application for subcutaneous starting dose in early Alzheimer’s is under priority review with action date May 24, 2026.
-
Eisai ranks 36th in Global 100 sustainability list
It marks Eisai's tenth inclusion and highest rank among global pharmaceutical companies. Evaluation based on UN SDGs, sustainable revenue, and investment.
Media coverage
-
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous I...
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three...
-
FDA extends review period for Eisai, Biogen Alzheimer’s drug By Investing.com
FDA extends review period for Eisai, Biogen Alzheimer’s drug...
-
Health Canada approves second drug targeting underlying cause of Alzheimer's disease
Health Canada has approved a second drug that targets the underlying cause of Alzheimer's disease, a development that could give Canadian patients more options to...
-
Application for pulmonary hypertension drug MD-712 in Japan
Motida Pharmaceutical announced on the 30th that it has submitted an approval application to the Ministry of Health, Labour and Welfare for 'MD-712' (development code, generic name = treprostinil), which it has been developing as a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease...
Track Eisai and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore